Robert J. Spiegel
CIK 1492256 · Chief Medical Officer · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$733.6K
Companies
10
Total Filings
116
Lifetime Open-Market Net
-$725.9K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GERN | Director | 205,810 | $1.63 | $335.5K | -$719.2K | 68 | 2026-07-01 |
| RNXT | Director | 40,983 | $1.15 | $47.1K | $0 | 5 | 2025-10-02 |
| Bio Green Med Solution, Inc. (CYCCP) Delisted | Director | 39,415 | $5.05 | $199.0K | $0 | 6 | 2023-07-03 |
| Athenex, Inc. (ATNX) Delisted | Director | 4,592 | $0.20 | $933 | $0 | 9 | 2023-04-24 |
| Old Ayala, Inc (AYLA) Delisted | Director | — | $0.50 | — | $0 | 2 | 2022-06-15 |
| PDSB | Director | 48,661 | $0.26 | $12.5K | $0 | 1 | 2019-03-18 |
| EDGE | Director | 1,933 | $51.64 | $99.8K | $33.0K | 5 | 2018-08-15 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | 0 | — | — | $0 | 5 | 2018-02-13 |
| PTCT | Chief Medical Officer | 3,239 | $73.70 | $238.7K | -$39.7K | 5 | 2016-01-06 |
| CAPS | Director | 10 | $0.32 | $3 | $0 | 3 | 2012-01-03 |
Recent Filings · Page 8 of 12
116 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-20 | EDGE | Grant (A) | — | $0 | EDGAR |
| 2018-05-17 | GERN | Grant (A) | — | $0 | EDGAR |
| 2018-03-30 | GERN | Grant (A) | +1,691 | $0 | EDGAR |
| 2018-02-13 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Disp (D) | −5,130 | -$92.3K | EDGAR |
| 2018-01-02 | GERN | Grant (A) | +3,993 | $0 | EDGAR |
| 2017-10-02 | GERN | Grant (A) | +3,297 | $0 | EDGAR |
| 2017-06-30 | GERN | Grant (A) | +2,595 | $0 | EDGAR |
| 2017-06-21 | EDGE | Grant (A) | — | $0 | EDGAR |
| 2017-06-05 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +5,130 | $0 | EDGAR |
| 2017-05-10 | GERN | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.